Zusammenfassung
Nachdem zunächst die therapeutische Beeinflussung der kognitiven Defizite bei Patienten mit einer Demenz vom Alzheimer Typ (DAT) ganz im Vordergrund stand, wird in letzter Zeit zunehmend den psychopathologischen Symptomen und Verhaltensstörungen (Behavioral and Psychological Symptoms of Dementia, BPSD) Beachtung geschenkt. Häufig sind nämlich gerade diese für die Betroffenen und für die sie versorgenden Personen erheblich belastend. Die Therapiemöglichkeiten sind mit der Zulassung von Azetyl-Cholinesterase-Inhibitoren (AChEI) der zweiten Generation in den letzten Jahren erweitert worden. Bei der klinischen Evaluation dieser Medikamente wurden zunächst deren Effekte auf die kognitiven Funktionen und Alltagsfertigkeiten bei DAT-Patienten untersucht. Zwischenzeitlich mehren sich Berichte, nach denen eine cholinerge Therapie auch BPSD bei DAT-Patienten günstig beeinflussen kann. Dadurch kann eine deutliche Entlastung der Patienten und Verminderung des Pflegebedarfs erreicht werden. Die Datenlage bezüglich der drei am Markt eingeführten AChEI spricht eindeutig für einen günstigen Einfluss im Sinne der Symptomreduktion oder der Symptomstabilisierung auf die BPSD in ihrer Gesamtheit. Es liegen zunehmend Hinweise dafür vor, dass es spezifische Symptomgruppen gibt, die besonders positiv auf die AChEI-Therapie ansprechen. Halluzinationen, depressive Symptome, Aggressivität und Reizbarkeit zeigen deutliche Symptomreduktionen unter einer Behandlung mit AChEI.
Abstract
The treatment of the cognitive deficits has been the major focus in patients with Alzheimer's disease (DAT) so far. Recently there is increasing interest in Behavioral and Psychological Symptoms of Dementia (BPSD), which can place much burden on DAT patients and their caregivers. With the introduction of Acetylcholinesterase Inhibitors (AChEI) of the second generation the therapeutic armament has been extended. The clinical evaluation of AChEI has found growing evidence that these compounds do not only improve cognitive abilities and activities of daily living (ADL), but also BPSD. The given data regarding the three AChEI available on the market allow the conclusion that there is a general improvement in BPSD. Beside these particularly positive effects on hallucinations, mood symptoms, aggressiveness, and agitation seem possible but need further clarification.
Literatur
1
Burns A, Jacoby R, Levy R.
Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour.
Br J Psychiatry.
1990;
157
86-94
2
Mega M S, Cummings J L, Fiorello T, Gornbein J.
The spectrum of behavioural changes in Alzheimer's disease.
Neurology.
1996;
46
130-135
3
Cummings J L, Masterman D L.
Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.
J Clin Psychiatry.
1998;
59 (suppl 13)
23-30
4
Rabins P V, Mace N L, Lucas M J.
The impact of dementia on the family.
JAMA.
1982;
248
333-335
5
Pruchno R A, Resch N L.
Aberrant behaviors and Alzheimer's disease: mental health effect on spouse caregivers.
J Gerontol.
1989;
44
177-182
6
Ballard C, Lowery K, Powell I, O'Brien J, James I.
Impact of behavioural and psychological symptoms of dementia on caregivers.
Int Psychogeriatr.
2000;
12
93-105
7
Stoppe G, Staedt J.
Psychopharmakotherapie von Verhaltensstörungen bei Demenzkranken.
Z Gerontol Geriatr.
1999;
32
153-158
8
Rösler M, Retz W, Retz-Junginger P, Dennler H J.
Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease.
Behav Neurol.
1998/1999;
11
211-216
9
Arendt T.
Das Syndrom der partiellen cholinergen Deafferentierung des kortikalen Mantels - ein Konzept zur Beschreibung des brain-behaviour-relationships bei dementiellen Erkrankungen.
Fortschr Neurol Psychiat.
1991;
59
81-91
10
Whitehouse P J, Price D L, Clark A W, Coyle J T, DeLong M R.
Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis.
Ann Neurol.
1981;
10
122-126
11
Gsell W, Strein I, Riederer P.
The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared.
J Neural Transm Suppl.
1996;
47
73-101
12
Kaufer D I, Cummings J L, Christine D.
Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study.
J Geriatr Psychiatry Neurol.
1996;
9
1-6
13
Perry E, Ballard C, Spurden D, Cheng A, Johnson M, McKeith I, Piggott M, Perry R.
Cholinergic systems in the human brain: psychopharmacology and psychosis.
Alz Dis Rev.
1998;
3
117-124
14 Ballard C, Lowery K, Harrison R, McKeith I G. Noncognitive symptoms in Lewy body dementia. In: Perry R (Hrsg.). Dementia with Lewy Bodies Cambridge: Cambridge University Press 1996: 67-84
15
Perry E K, Haroutunian V, Davis K L, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith I G, Perry R H.
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.
Neuroreport.
1994;
55
1454-1456
16
Cummings J L, Back C.
The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease.
Am J Geriatr Psychiatry.
1998;
6
64-78
17
Janowsky D S, Risch S C, Gillin J C.
Adrenergic-cholinergic balance and the treatment of affective disorders.
Prog Neuropsychopharmacol Biol Psychiatry.
1983;
7
297-307
18 Schmidt B H, Hinz V C, Blokland A. Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. In: Becker R, Giacobini E (Hrsg.). Alzheimer Disease: from molecular Biology to Therapy Boston: Birkhäuser 1996: 217-221
19
Becker R E, Colliver J A, Markwell S J, Moriearty P L, Unni L K, Vicari S.
Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease.
Alzheimer Dis Assoc Disord.
1996;
10
124-131
20
Becker R E, Colliver J A, Markwell S J, Moriearty P L, Unni L K, Vicari S.
Effects of metrifonate on cognitive decline in Alzheimer's disease: a double-blind, placebo-controlled, 6-month study.
Alzheimer Dis Assoc Disord.
1998;
12
54-57
21
Cummings J I, Cyrus P A, Bieber F, Mas J, Orazem J, Gulanski B.
Metrifonate treatment of the cognitive deficits of Alzheimer's disease.
Neurology.
1998;
50
1214-1221
22
Morris J C, Cyrus P A, Orazam J, Mas J, Bieber F, Ruzicka B B, Gulanski B.
Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease.
Neurology.
1998;
50
1222-1230
23
Ringmann J M, Cummings J L.
Metrifonate: Update on a new antidementia agent.
J Clin Psychiatry.
1999;
60
776-782
24
Cummings J L, Mega M, Gray K, Rosenberg-Thompson S, Carusi D A, Gornbein J.
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.
Neurology.
1994;
44
2308-2314
25
Rosen W G, Mohs R C, Davis K L.
A new rating scale for Alzheimer's disease.
Am J Psychiatry.
1984;
141
1356-1364
26
Raskind M A, Cyrus P A, Ruzicka B B, Gulanski B I.
The effects of metrifonate on the cognitive, behavioural, and functional performance of Alzheimer's disease patients.
J Clin Psychiatry.
1999;
60
318-325
27
Cummings J L, Cyrus P A, Ruzicka B B.
The efficacy of metrifonate in improving the behavioural disturbance of Alzheimer's disease patients.
Neurology.
1998;
50 (suppl 4)
A251
28
Gelinas I, Gauthier S, Cyrus P A.
The efficacy of metrifonate in enhancing the ability of Alzheimer's disease patients to perform basic and instrumental activities of daily living.
Neurology.
1998;
50 (suppl 4)
A90-A91
29
Shikiar R, Shakespeare A, Sagnier P P, Wilkinson D, McKeith I, Dartigues J F, Dubois B.
The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial.
JAGS.
2000;
48
268-274
30 Möller H J. Beispiele klinischer Prüfmodelle für den Wirksamkeitsnachweis von Nootropika. In: Lungershausen E (Hrsg.). Demenz: Herausforderung für Forschung, Medizin und Gesellschaft Berlin, Heidelberg, New York, Tokyo: Springer 1992: 147-157
31
Farlow M, Gracon S I, Hershey L A, Lewis K W, Sadowsky C H, Dolan-Ureno J.
A controlled trial of tacrine in Alzheimer's disease.
JAMA.
1992;
268
2523-2529
32
Knapp M J, Knopman D S, Solomon P R.
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease.
JAMA.
1994;
271
985-991
33
Kaufer D, Cummings J L, Christine D.
Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity.
Neuropsychiatry Clin Neurosci.
1998;
10
55-63
34
Rogers S L, Doody R S, Mohs R C, Friedhoff L T.
Donezepil HCL (E2020) improves cognitive and global function in patients with mild to moderately severe Alzheimer's disease: results of a 15-week phase III study.
Poster, 35th Anual Meeting of the ACNP.
1996;
9-13
35
Rogers S L, Farlow M R, Doody R S, Mohs R C, Friedhoff L T.
A 24-week, doubleblind placebocontrolled trial of Donezepil in patients with Alzheimer's disease.
Neurology.
1998;
50
136-145
36
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H J, Rogers S L, Friedhoff L T.
The effects of donezepil in Alzheimer's disease - results from a multinational trial.
Dement Geriatr Cogn Disord.
1999;
10
237-244
37
Tariot P N, Mack J L, Patterson M B, Edland S D, Weiner M F, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer J A, Stern Y.
The behavioral rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's disease.
Am J Psychiatry.
1995;
152
1349-1357
38
Weiner M F, Martin-Cock K, Foster B M, Saine K, Fontaine C S, Svetlik D A.
Effects of Donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
J Clin Psychiatry.
2000;
61
487-492
39
Mega M S, Masterman D M, O'Connor S M, Barclay T R, Cummings J L.
The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer's disease.
Arch Neurol.
1999;
56
1388-1393
40
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E.
A 24-week, randomised double-blind study of donepezil in moderate to severe Alzheimer's disease.
Neurology.
2001;
57
613-620
41
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm A L, Zhang R, Haglund A, Subbiah P.
A 1-year, randomised, placebo-controlled study of donezepil in patients with mild to moderate AD.
Neurology.
2001;
57
489-495
42
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stählin H B, Hartman R, Gharabawi M.
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
BMJ.
1999;
318
633-640
43
Corey-Bloom J, Anand R, Veach J.
A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetyl cholinesterase inhibitor, in patients with mild to mederatey severe Alzheimer's disease.
Int J Geriatr Psychopharmacol.
1998;
1
55-65
44
Reisberg B, Borenstein J, Salob S P, Ferris S H, Franssen E, Georgotas A.
Behavioral symptoms in Alzheimer's disease: phenomenology and treatment.
J Clin Psychiatry.
1987;
48 Suppl
9-15
45
Cummings J, Anand R, Koumaras B, Hartman R.
Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial.
Neurology.
2000;
54 (Suppl 3)
A468
46
McKeith I G, Grace J B, Walker Z, Byrne E J, Wilkinson D, Stevens T, Perry E K.
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
Int J Geriat Psychiatry.
2000;
15
387-392
47
Proskurnina N F, Yakovleva A P.
Alkaloids of Galanthus woronowi. II. Isolation of a new alkaloid.
Zh Obshch Khim (J Gen Chem).
1952;
22
1899-1902
48 Thomsen T, Kewitz H. Galanthamine treatment in senile dementia of Alzheimer's type: a case report. In: Kewitz H, Thomsen T, Bickel U (Hrsg.). Pharmacological Interventions on central cholinergic Mechanisms in senile Dementia (Alzheimer's Disease) München: W. Zuckschwerdt 1989: 238-241
49
Snorrason E, Steffansson J.
Galanthamine hydrobromide in mania.
Lancet.
1991;
337
557
50
Vovin R, Fakturovich A, Golenkov A, Lukin V.
Correction of apathetic-abulic manifestations of schizophrenia with cholinotropic drugs.
Zh Nevropatol Psikhiatr Im SS Korsakova.
1991;
91
111-115
51
Tariot P N, Solomon P R, Morris J C, Kershaw P, Lilienfeld S, Ding C.
A 5-month, randomised, placebo-controlled trial of galantamine in AD.
Neurology.
2000;
54
2269-2276
52
Wilcock G K, Lilienfeld S, Gaens E.
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial.
BMJ.
2000;
321
1-7
53
Imbimbo B P, Troetel W M, Martelli P, Lucchelli F. and the Eptastigmine Study Group .
A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.
Dement Geriatr Cogn Disord.
2000;
11(1)
17-24
54
Canal N, Imbimbo B P. for the Eptastigmine Study Group .
Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease.
Clin Pharmacol Ther.
1996;
60
218-228
55
Imbimbo B P, Martelli P, Troetel W M, Lucchelli F, Lucca U, Thal L J.
Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
Neurology.
1999;
52
700-708
56
Imbimbo B, Verdelli G, Martelli P, Marchesini D. and the Eptastigmine Study Group .
Two-year treatment of Alzheimer's disease with eptastigmine.
Dement Geriatr Cogn Disord.
1999;
10
139-147
57
Frey U, Retz W, Riederer P, Rösler M.
Neue Aspekte in der antidementiven Pharmakotherapie der Alzheimer-Erkrankung.
Akt Neurol.
2000;
27
305-317
58
Anand R, Gharabawi G, Enz A.
Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview.
J Drug Dev Clin Pract.
1996;
8
109-116
59
Greig N H, Utsuki T, Yu Q , Zhu X, Holloway H, Perry T A, Lee B, Ingram D, Lahiri D B.
A new therapeutic target in Alzheimer's disease: attention to butyrylcholinesterase.
Cur Med Res Opinion.
2001;
17
1-7
60
Maelicke A, Schröder H, Schrattenholz A.
Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system.
Semin Neurosci.
1995;
7
103-114
61
Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque E X.
Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.
Behav Brain Res.
2000;
113
199-206
Prof. Dr. M. Rösler
Universitätsnervenklinik · Universitätskliniken des Saarlandes
66421 Homburg